Xenetic Biosciences, Inc. (NASDAQ:XBIO) | WebDisclosure

Basculer en Français

10813	Companies
234252	Keywords
163045	Articles
125264	Press releases

Headlines Articles Press releases Xenetic Biosciences, Inc.

Home
Companies
Xenetic Biosciences, Inc.

PRESS RELEASE

published on 12/05/2024 at 14:45, 1 year 8 months ago

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program
Xenetic Biosciences partners with PeriNess to advance clinical proof-of-concept studies for systemic DNase I treatment in pancreatic and colorectal cancers. Collaboration aims to leverage expertize and improve therapeutic responses

Xenetic Biosciences Clinical Development Pancreatic Cancer PeriNess Systemic DNase I
BRIEF

published on 11/22/2024 at 15:20, 1 year 8 months ago

Xenetic Biosciences Shares Insights on DNase I Efficacy in Cancer Treatment

Xenetic Biosciences Cancer Treatment Preclinical Data DNase I Immune Checkpoint Blockade
BRIEF

published on 11/22/2024 at 15:20, 1 year 8 months ago

Xenetic Biosciences partage ses connaissances sur l'efficacité de la DNase I dans le traitement du cancer

Traitement Du Cancer Biosciences Xénétiques Données Précliniques ADNase I Blocage Du Point De Contrôle Immunitaire
PRESS RELEASE

published on 11/22/2024 at 15:15, 1 year 8 months ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, presents positive preclinical data at SITC 39th Annual Meeting. Focus on advancing immune-oncology technologies to treat hard cancers

Cancer Treatment Preclinical Data Immunotherapy SITC 39th Annual Meeting Dr. Reid Bissonnette
BRIEF

published on 11/21/2024 at 14:35, 1 year 8 months ago

Xenetic Biosciences annonce des résultats précliniques prometteurs pour la thérapie par ADNase I et cellules CAR T dans le mélanome

Étude Préclinique Mélanome ADNase I Cellules CAR-T Thérapie Oncologique
BRIEF

published on 11/21/2024 at 14:35, 1 year 8 months ago

Xenetic Biosciences Reports Promising Preclinical Results for DNase I and CAR T Cell Therapy in Melanoma

Preclinical Study Melanoma DNase I CAR T Cells Oncology Therapy
PRESS RELEASE

published on 11/21/2024 at 14:30, 1 year 8 months ago

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Xenetic presents preclinical data on DNase I and CAR T cells' synergistic effects in treating solid tumors. Results show promise in modulating tumor microenvironment and enhancing therapeutic responses

Preclinical Data Solid Tumors Xenetic DNase I CAR T Cells
BRIEF

published on 11/13/2024 at 14:35, 1 year 8 months ago

Xenetic Biosciences publie ses résultats financiers du troisième trimestre 2024

Résultats Financiers Développement Clinique Biosciences Xénétiques Plateforme D'oncologie DNase Partenariats Institutionnels
BRIEF

published on 11/13/2024 at 14:35, 1 year 8 months ago

Xenetic Biosciences Reports Q3 2024 Financial Results

Financial Results Xenetic Biosciences Clinical Development DNase Oncology Platform Institutional Partnerships
PRESS RELEASE

published on 11/13/2024 at 14:30, 1 year 8 months ago

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
Xenetic Biosciences reports Q3 2024 financial results, progress in DNase-based platform for oncology, partnership with institutional collaborators, and $6.8 million cash balance

Xenetic Biosciences Oncology Q3 2024 Financial Results Institutional Partnerships DNase-based Platform

Accesswire

Published on 08/08/2026 at 00:00, 2 days 2 hours ago

Boron One Announces Change of Auditor
Published on 08/07/2026 at 23:15, 2 days 3 hours ago

Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 2 days 3 hours ago

Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Published on 08/07/2026 at 22:30, 2 days 3 hours ago

UraniumX Deploys $3.8 Million to Athabasca Basin Exploration
Published on 08/07/2026 at 22:15, 2 days 4 hours ago

Noram Lithium Engages 1353656 BC Ltd. for Marketing and Management Consulting Services

View all ACCESSWIRE

EQS Group

Published on 08/10/2026 at 00:05, 2 hours 11 minutes ago

Games of the Future Astana 2026 Comes to a Close After 12 Electric Days of Competition
Published on 08/09/2026 at 15:05, 11 hours 11 minutes ago

GearUP and Escape from Tarkov Partner to Enhance Online Gaming Experience for the New Season
Published on 08/09/2026 at 00:01, 1 day 2 hours ago

Club Offers for Travel Enthusiasts in Germany
Published on 08/08/2026 at 16:25, 1 day 9 hours ago

Bybit Sues North Korea and Lazarus Group, Secures Preliminary Injunction Freezing Stolen Assets in Landmark Crypto Asset Recovery Effort
Published on 08/07/2026 at 23:21, 2 days 2 hours ago

EQS-Adhoc: Northern Data Group reports Q2 2026 including the adverse fair value movement on contingent consideration

Les Echos

Published on 08/07/2026 at 18:54, 2 days 7 hours ago

Covivio - Déclaration des transactions sur actions propres réalisées du 03 août 2026 au 07 août 2026
Published on 08/07/2026 at 18:54, 2 days 7 hours ago

Covivio - Information on Treasury shares transactions between August 3rd, 2026, and August 7th, 2026
Published on 08/07/2026 at 18:40, 2 days 7 hours ago

Disclosure of transactions in own shares from August 3 to August 7, 2026
Published on 08/07/2026 at 18:40, 2 days 7 hours ago

Déclaration hebdomadaire d'opérations effectuées du 3 au 7 août 2026
Published on 08/07/2026 at 18:00, 2 days 8 hours ago

LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 juillet 2026

View all LES ECHOS COMFI WIRE